Johnson & Johnson's Icotyde Receives FDA Approval
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 18 2026
0mins
Should l Buy JNJ?
Source: CNBC
- FDA Approval: Johnson & Johnson's oral medication Icotyde has received FDA approval, becoming the first oral option for treating moderate to severe plaque psoriasis, expected to serve as the first-line systemic treatment between topical and injectable therapies.
- Significant Market Potential: J&J anticipates that Icotyde could exceed $5 billion in annual sales once approved for other autoimmune conditions, highlighting its substantial potential in the competitive psoriasis treatment market.
- Increased Patient Acceptance: The oral formulation of Icotyde is likely to appeal to approximately 75% of the 8 million U.S. psoriasis patients who do not transition from topical treatments to injections due to needle phobia, potentially enhancing patient adherence to treatment.
- Changing Competitive Landscape: Icotyde targets the same IL-23 receptor as J&J's Tremfya and AbbVie's Skyrizi, offering a relatively simple and safe treatment option that could alter the competitive dynamics in psoriasis treatment.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy JNJ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on JNJ
Wall Street analysts forecast JNJ stock price to fall
20 Analyst Rating
13 Buy
7 Hold
0 Sell
Moderate Buy
Current: 221.320
Low
190.00
Averages
218.50
High
240.00
Current: 221.320
Low
190.00
Averages
218.50
High
240.00
About JNJ
Johnson & Johnson and its subsidiaries are engaged in the research and development, manufacture, and sale of a range of products in the healthcare field. The Company’s segments include Innovative Medicine and MedTech. The Innovative Medicine segment is focused on various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, cardiovascular and metabolism. Its products include REMICADE (infliximab), SIMPONI (golimumab), SIMPONI ARIA (golimumab), STELARA (ustekinumab), TREMFYA (guselkumab), EDURANT (rilpivirine), and INVEGA SUSTENNA/XEPLION (paliperidone palmitate). The MedTech segment includes a portfolio of products used in cardiovascular, orthopedics, surgery, and vision categories. The Cardiovascular portfolio includes electrophysiology products to treat heart rhythm disorders and circulatory restoration products (Shockwave) for the treatment of calcified coronary artery disease (CAD) and peripheral artery disease (PAD).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Bristol Myers Squibb Faces Patent Cliff Challenges
- Weak Sales Growth: Bristol Myers Squibb's first-quarter revenue grew only 3% year-over-year to $11.5 billion, with Eliquis and Opdivo accounting for over half at $6.3 billion, indicating pressure on the company's medium-term outlook that may affect shareholder confidence.
- Strong New Product Performance: Despite facing patent expiration risks, Reblozyl saw a 16% year-over-year sales increase to $555 million in Q1, while the new Opdivo Qvantig surged over 200% to $163 million, showcasing the company's potential in new product development.
- Pipeline Progress is Crucial: Bristol Myers is conducting dozens of clinical trials, with Milvexian, a next-gen anticoagulant, expected to generate over $1 billion in annual sales if successful, which could help replace Eliquis and enhance the company's market competitiveness.
- Attractive Long-Term Investment: Although current sales growth is slow, Bristol Myers trades at a forward P/E of 9, below the healthcare sector average of 16.8, and with a strong pipeline and stable dividend yield, long-term investors should consider the stock's potential value.
See More
Bristol Myers Squibb Faces Patent Cliffs Ahead
- Patent Cliff Risks: Bristol Myers Squibb is set to face more patent cliffs in the coming years, with its two best-selling drugs, Opdivo and Eliquis, losing patent protection by the end of the decade, which could lead to significant underperformance against broader equities and potentially be a wealth destroyer over the next five years.
- New Drug Sales Growth: Despite challenges, the company reported a 3% year-over-year revenue increase in Q1 to $11.5 billion, with Eliquis and Opdivo accounting for over 60% of sales, indicating potential in new drug sales, particularly with Reblozyl's 16% growth to $555 million.
- Pipeline Outlook: The next-generation anticoagulant Milvexian, currently in phase 3 trials, is expected to generate over $1 billion in annual sales if successful, potentially replacing Eliquis and enhancing the company's competitive position in the anticoagulant market.
- Attractive Valuation and Dividends: Trading at 9x forward earnings, significantly below the healthcare sector average of 16.8, and offering a 4.5% dividend yield, Bristol Myers Squibb remains appealing to value investors and income seekers, despite short-term sales growth challenges, due to its strong pipeline and growth potential.
See More
Johnson & Johnson to Attend Goldman Sachs Global Healthcare Conference
- Conference Participation: Johnson & Johnson will participate in the Goldman Sachs 47th Annual Global Healthcare Conference on June 9, 2026, with management engaging in a Fireside Chat at 10:00 a.m. Eastern Time to showcase the company's latest developments and strategic direction in healthcare.
- Investor Engagement: The Fireside Chat will be live-streamed on Johnson & Johnson's official website, allowing investors and other interested parties to access real-time information, thereby enhancing interaction and transparency with stakeholders.
- Replay Availability: An audio replay of the webcast will be available approximately 48 hours after the live event, ensuring that investors who cannot attend in real-time can still access the content, further improving information accessibility and corporate transparency.
- Media and Investor Contacts: Johnson & Johnson has provided dedicated media and investor contact emails, media-relations@its.jnj.com and investor-relations@its.jnj.com, respectively, facilitating further inquiries and support, thereby strengthening communication with external stakeholders.
See More
Navigating Growth vs. Income Stocks Amid Market Volatility
- Market Volatility Analysis: Equity markets have faced significant volatility this year due to rising inflation, geopolitical tensions, and potential recession, yet the S&P 500 has still risen by 7%, indicating market resilience.
- Growth Stock Potential: Eli Lilly exemplifies growth potential, with a 56% year-over-year revenue increase to $19.8 billion in Q1, showcasing its dominance in the weight-loss drug market and the likelihood of launching more drugs in the next five years, appealing to high-risk investors.
- Income Stock Stability: Johnson & Johnson, a 'Dividend King' with 64 consecutive years of dividend increases, offers a 2.35% dividend yield, making it suitable for income-seeking investors, particularly those nearing retirement who prefer stability.
- Investment Strategy Considerations: In the current market environment, investors must weigh their personal investment goals and risk tolerance when choosing between growth and income stocks to achieve optimal returns.
See More
Investors' Dilemma: Growth vs. Dividend Stocks
- Market Volatility Impact: The equity markets have faced significant volatility this year due to rising inflation, geopolitical tensions, and potential recession, yet the S&P 500 has still risen by 7%, indicating market resilience.
- Growth Stocks' Risk and Reward: Growth stocks tend to be more volatile and may suffer greater losses during economic downturns; however, for long-term investors, market crashes can present opportunities to buy at lower prices, potentially leading to higher returns.
- Stability of Dividend Stocks: Dividend stocks like Johnson & Johnson provide lower volatility and long-term returns for investors nearing retirement, with a remarkable record of 64 consecutive years of dividend increases, showcasing their reliability.
- Eli Lilly's Growth Potential: Eli Lilly reported a 56% year-over-year revenue increase in Q1, reaching $19.8 billion, with earnings per share at $8.26, highlighting its dominance in the weight-loss drug market and promising future growth prospects.
See More
In-Depth Analysis of Strong Holdings
- Holding Analysis: In the latest 13F filings, 64 hedge funds held Johnson & Johnson (JNJ), indicating widespread interest in the stock, although these reports only reflect long positions.
- Position Changes: As of March 31, 2026, 19 funds increased their JNJ holdings while 34 decreased theirs, showcasing a divergence in market sentiment towards the stock.
- Aggregate Growth: The total holdings of hedge funds in JNJ rose from 349,344,815 shares on December 31, 2025, to 603,016,125 shares, representing an increase of approximately 72.61%, reflecting strong confidence in the company.
- Key Fund Movements: Guardian Capital LLC exited its JNJ position in the latest 13F filings, indicating varying investment strategies and risk assessments within the market.
See More
Bristol Myers Squibb Faces Patent Cliff Challenges
- Weak Sales Growth: Bristol Myers Squibb's first-quarter revenue grew only 3% year-over-year to $11.5 billion, with Eliquis and Opdivo accounting for over half at $6.3 billion, indicating pressure on the company's medium-term outlook that may affect shareholder confidence.
- Strong New Product Performance: Despite facing patent expiration risks, Reblozyl saw a 16% year-over-year sales increase to $555 million in Q1, while the new Opdivo Qvantig surged over 200% to $163 million, showcasing the company's potential in new product development.
- Pipeline Progress is Crucial: Bristol Myers is conducting dozens of clinical trials, with Milvexian, a next-gen anticoagulant, expected to generate over $1 billion in annual sales if successful, which could help replace Eliquis and enhance the company's market competitiveness.
- Attractive Long-Term Investment: Although current sales growth is slow, Bristol Myers trades at a forward P/E of 9, below the healthcare sector average of 16.8, and with a strong pipeline and stable dividend yield, long-term investors should consider the stock's potential value.
See More
Bristol Myers Squibb Faces Patent Cliffs Ahead
- Patent Cliff Risks: Bristol Myers Squibb is set to face more patent cliffs in the coming years, with its two best-selling drugs, Opdivo and Eliquis, losing patent protection by the end of the decade, which could lead to significant underperformance against broader equities and potentially be a wealth destroyer over the next five years.
- New Drug Sales Growth: Despite challenges, the company reported a 3% year-over-year revenue increase in Q1 to $11.5 billion, with Eliquis and Opdivo accounting for over 60% of sales, indicating potential in new drug sales, particularly with Reblozyl's 16% growth to $555 million.
- Pipeline Outlook: The next-generation anticoagulant Milvexian, currently in phase 3 trials, is expected to generate over $1 billion in annual sales if successful, potentially replacing Eliquis and enhancing the company's competitive position in the anticoagulant market.
- Attractive Valuation and Dividends: Trading at 9x forward earnings, significantly below the healthcare sector average of 16.8, and offering a 4.5% dividend yield, Bristol Myers Squibb remains appealing to value investors and income seekers, despite short-term sales growth challenges, due to its strong pipeline and growth potential.
See More
Johnson & Johnson to Attend Goldman Sachs Global Healthcare Conference
- Conference Participation: Johnson & Johnson will participate in the Goldman Sachs 47th Annual Global Healthcare Conference on June 9, 2026, with management engaging in a Fireside Chat at 10:00 a.m. Eastern Time to showcase the company's latest developments and strategic direction in healthcare.
- Investor Engagement: The Fireside Chat will be live-streamed on Johnson & Johnson's official website, allowing investors and other interested parties to access real-time information, thereby enhancing interaction and transparency with stakeholders.
- Replay Availability: An audio replay of the webcast will be available approximately 48 hours after the live event, ensuring that investors who cannot attend in real-time can still access the content, further improving information accessibility and corporate transparency.
- Media and Investor Contacts: Johnson & Johnson has provided dedicated media and investor contact emails, media-relations@its.jnj.com and investor-relations@its.jnj.com, respectively, facilitating further inquiries and support, thereby strengthening communication with external stakeholders.
See More
Navigating Growth vs. Income Stocks Amid Market Volatility
- Market Volatility Analysis: Equity markets have faced significant volatility this year due to rising inflation, geopolitical tensions, and potential recession, yet the S&P 500 has still risen by 7%, indicating market resilience.
- Growth Stock Potential: Eli Lilly exemplifies growth potential, with a 56% year-over-year revenue increase to $19.8 billion in Q1, showcasing its dominance in the weight-loss drug market and the likelihood of launching more drugs in the next five years, appealing to high-risk investors.
- Income Stock Stability: Johnson & Johnson, a 'Dividend King' with 64 consecutive years of dividend increases, offers a 2.35% dividend yield, making it suitable for income-seeking investors, particularly those nearing retirement who prefer stability.
- Investment Strategy Considerations: In the current market environment, investors must weigh their personal investment goals and risk tolerance when choosing between growth and income stocks to achieve optimal returns.
See More
Investors' Dilemma: Growth vs. Dividend Stocks
- Market Volatility Impact: The equity markets have faced significant volatility this year due to rising inflation, geopolitical tensions, and potential recession, yet the S&P 500 has still risen by 7%, indicating market resilience.
- Growth Stocks' Risk and Reward: Growth stocks tend to be more volatile and may suffer greater losses during economic downturns; however, for long-term investors, market crashes can present opportunities to buy at lower prices, potentially leading to higher returns.
- Stability of Dividend Stocks: Dividend stocks like Johnson & Johnson provide lower volatility and long-term returns for investors nearing retirement, with a remarkable record of 64 consecutive years of dividend increases, showcasing their reliability.
- Eli Lilly's Growth Potential: Eli Lilly reported a 56% year-over-year revenue increase in Q1, reaching $19.8 billion, with earnings per share at $8.26, highlighting its dominance in the weight-loss drug market and promising future growth prospects.
See More
In-Depth Analysis of Strong Holdings
- Holding Analysis: In the latest 13F filings, 64 hedge funds held Johnson & Johnson (JNJ), indicating widespread interest in the stock, although these reports only reflect long positions.
- Position Changes: As of March 31, 2026, 19 funds increased their JNJ holdings while 34 decreased theirs, showcasing a divergence in market sentiment towards the stock.
- Aggregate Growth: The total holdings of hedge funds in JNJ rose from 349,344,815 shares on December 31, 2025, to 603,016,125 shares, representing an increase of approximately 72.61%, reflecting strong confidence in the company.
- Key Fund Movements: Guardian Capital LLC exited its JNJ position in the latest 13F filings, indicating varying investment strategies and risk assessments within the market.
See More
